Baxter wins court order in Bayer espionage case

Related tags Baxter

A judge has ordered an employee at Bayer's US subsidiary to hand
files over to the court in a lawsuit brought by Baxter alleging
industrial espionage.

A judge has ordered an employee at Bayer's US subsidiary to hand over documents and computer files to the court in a lawsuit brought by Baxter alleging industrial espionage.

Gopal Dasari, a former Baxter employee who joined Bayer earlier this year, stands accused of copying trade secrets relating to the manufacturing processes used for a number of Baxter's biopharmaceutical products.

Judge Jeffrey White ordered Bayer not to copy or review any files on Dasari's computers, according to a Bloomberg report.

Dasari worked for Baxter for approximately six years and during that time was involved in a number of projects, including one to improve the manufacturing process for the firm's billion-dollar haemophilia treatment Recombinate (antihaemophilic factor). Bayer manufactures a rival product called Kogenate (recombinant Factor VIII).

Baxter is also seeking damages for its actual losses, plus punitive damages and triple damages under California's trade secrets statute.

Meantime, Baxter has been granted US approval for a new plasma- and albumin-free formulation of recombinant antihaemophilic factor called Advate. It is produced in genetically engineered Chinese hamster ovary cells that have been altered to produce factor VIII.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars